Retigabine
Clinical data | |
---|---|
Trade names | Trobalt, Potiga |
Other names | D-23129, ezogabine (USAN US) |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a612028 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 60% |
Protein binding | 60–80% |
Metabolism | Liver glucuronidation and acetylation. CYP not involved |
Elimination half-life | 8 hours (mean), range: 7–11 hours[1] |
Excretion | Kidney (84%) |
Identifiers | |
| |
JSmol) | |
| |
|
Retigabine (
Retigabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain.[5][6][7] This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including tinnitus, migraine and neuropathic pain. The manufacturer withdrew retigabine from clinical use in 2017.
Adverse effects
The adverse effects found in the Phase II trial mainly affected the central nervous system, and appeared to be dose-related.[8] The most common adverse effects were drowsiness, dizziness, tinnitus and vertigo, confusion, and slurred speech.[9] Less common side effects included tremor, memory loss, gait disturbances, and double vision.[10] In 2013, FDA warned the public that Potiga (ezogabine) can cause blue skin discoloration and eye abnormalities characterized by pigment changes in the retina. FDA does not currently know if these changes are reversible. FDA is working with the manufacturer to gather and evaluate all available information to better understand these events. FDA will update the public when more information is available.[11] Psychiatric symptoms and difficulty urinating have also been reported, with most cases occurring in the first 2 months of treatment.[12][13]
Interactions
Retigabine appears to be free of
Concomitant use of retigabine and digoxin may increase serum concentration of the latter. In vitro studies suggest that the main metabolite of retigabine acts as a P-glycoprotein inhibitor, and may thus increase absorption and reduce elimination of digoxin.[13]
Pharmacology
Mechanism of action
Retigabine acts as a neuronal KCNQ/Kv7 potassium channel opener, a mechanism of action markedly different from that of any current anticonvulsants.[5][6][7] This mechanism of action is similar to that of the chemically similar flupirtine,[15] which is used mainly for its analgesic properties.
The term "channel opener" refers to a shift in the voltage dependence for channel opening towards more negative potentials. This means that KCNQ/Kv7 channels open at more negative potentials in the presence of Retigabine. Recently, it has also been shown that Retigabine stabilizes the open Kv7.2/7.3 channel, making deactivation slower with little change in voltage dependence. This effect of Retigabine is observed at concentrations below 10 micromolar.[16] A similar effect is observed on the homomeric Kv7.2 channel.[17]
Pharmacokinetics
Retigabine is quickly absorbed, and reaches maximum plasma concentrations between half an hour and 2 hours after a single oral dose. It has a moderately high oral bioavailability (50–60%), a high volume of distribution (6.2 L/kg), and a terminal half-life of 8 to 11 hours.[14] Retigabine requires thrice-daily dosing due to its short half-life.[8][9][13]
Retigabine is metabolized in the liver, by N-glucuronidation and acetylation. The cytochrome P450 system is not involved. Retigabine and its metabolites are excreted almost completely (84%) by the kidneys.[13][14]
History
Among the newer anticonvulsants, retigabine was one of the most widely studied in the
Clinical trials
In a
A Phase II trial meant to assess the safety and efficacy of retigabine for treating postherpetic neuralgia was completed in 2009, but failed to meet its primary endpoint. Preliminary results were reported by Valeant as "inconclusive".[19]
Regulatory approval
The U.S. Food and Drug Administration accepted Valeant's New Drug Application for retigabine on December 30, 2009.[20] The FDA Peripheral and Central Nervous System Drugs Advisory Committee met on August 11, 2010, to discuss the process and unanimously recommended approval of Potiga for the intended indication (add-on treatment of partial seizures in adults).[21][22] However, the possibility of urinary retention as an adverse effect was considered a significant concern, and the panel's members recommended that some sort of monitoring strategy be used to identify patients at risk of bladder dysfunction.[21] Potiga was approved by the FDA on June 10, 2010, but did not become available on the U.S. market until it had been scheduled by the Drug Enforcement Administration.[12]
In December 2011, the U.S. Drug Enforcement Administration (DEA) placed the substance into Schedule V of the Controlled Substances Act (CSA), the category for substances with a comparatively low potential for abuse. This became effective 15 December 2011.[23]
Name
The
References
- S2CID 5568963.
- ^ "POTIGA (ezogabine) Tablets, CV. Full Prescribing Information" (PDF). GlaxoSmithKline and Valeant Pharmaceuticals. Retrieved 4 June 2014.
- ^ https://assets.publishing.service.gov.uk/media/57fe4b6640f0b6713800000c/Trobalt_letter.pdf [bare URL PDF]
- ^ "Epilepsy drug Trobalt (retigabine) to be discontinued". epilepsysociety.org.uk. 14 September 2016.
- ^ PMID 9384239.
- ^ S2CID 11112809.
- ^ PMID 18590620.
- ^ PMID 18049722.
- ^ S2CID 23557118.
- ^ S2CID 24574886.
- ^ "Potiga (Ezogabine): Drug Safety Communication". Food and Drug Administration.
- ^ a b Hitt E (2011-06-13). "FDA approves ezogabine for seizures in adults". Medscape. Retrieved 2011-06-13.
- ^ a b c d e "Trobalt – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. 2011-05-05. Retrieved 2011-06-13.
- ^ S2CID 72918370.
- PMID 19298256.
- PMID 26880756.
- PMID 32636742.
- PMID 16621450.
- ^ "Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)" (Press release). PRNewswire. 2009-08-24. Retrieved 2011-06-13.
- ^ "Retigabine NDA accepted for filing" (Press release). PRNewswire. 2009-12-30. Retrieved 2010-07-19.
- ^ a b Lowry F (2010-08-12). "Epilepsy drug exogabine gets green light from FDA Advisory Panel". Medscape. Retrieved 2010-08-13.
- ^ [No authors listed] (2010-06-25). "August 11, 2010: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement". U.S. Food and Drug Administration. Retrieved 2010-07-19.
- ^ U.S. Drug Enforcement Administration (15 December 2011). "Schedules of Controlled Substances: Placement of Ezogabine Into Schedule V" (PDF). Federal Register. 76 (241).
- ^ World Health Organization (1996). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 215. Archived from the original (PDF) on June 27, 2004.
- ^ [No authors listed] (2005–2006). "Statement on a nonproprietary name adopted by the USAN council: Retigabine" (PDF). American Medical Association. Retrieved 2010-07-19.
- ^ [No authors listed] (2010). "Statement on a nonproprietary name adopted by the USAN council: Ezogabine" (PDF). American Medical Association. Archived from the original (PDF) on 2012-04-02. Retrieved 2010-07-19.
Further reading
- Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE (2005). "Retigabine: chemical synthesis to clinical application". CNS Drug Reviews. 11 (1): 1–20. PMID 15867950.
- Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C, et al. (May 1999). "Metabolism of retigabine (D-23129), a novel anticonvulsant". Drug Metabolism and Disposition. 27 (5): 613–622. PMID 10220491.